PancragenvsLivagen

Molecular Formula

C₂₆H₃₆N₆O₉

Molecular Weight

576.6 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids

Bioavailability

Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses

CAS Number

Not definitively assigned

Molecular Formula

C₁₈H₃₁N₅O₉

Molecular Weight

461.5 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)

Bioavailability

Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli

CAS Number

Not assigned (research compound)

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Minor digestive changes

Uncommon

• Mild hypoglycemia

Serious

• No documented serious adverse effects

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Digestive enzyme changes

Uncommon

• Transient flu-like symptoms

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
• xConcurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive autoimmune conditions in flare without physician supervision
• xConcurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism